41
Participants
Start Date
July 11, 2024
Primary Completion Date
July 31, 2029
Study Completion Date
July 31, 2029
B7-H3CART Dose (Intravenous)
"Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level -1 (DL-1) 0.3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 1 (DL1) 1 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 3 (DL3) 9 x 106 transduced T cells/kg"
RECRUITING
Stanford University, Palo Alto
Crystal Mackall, MD
OTHER